- Condition: Pain
Interventions: Drug: ULTRAM ER; Drug: ULTRAM ER
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed - verified April 2012 - Condition: Pain
Interventions: Drug: ULTRAM ER; Drug: ULTRAM ER
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed - verified April 2012 - Condition: Irregular Antibody Screening
Intervention:
Sponsors: Johnson & Johnson Medical, China; Johnson & Johnson Medical, China
Not yet recruiting - verified April 2012 - Condition: Hepatitis C
Intervention:
Sponsors: Johnson & Johnson Medical, China; Johnson & Johnson Medical, China
Recruiting - verified April 2012 - Condition: Schizophrenia
Intervention: Drug: Paliperidone ER
Sponsors: Johnson & Johnson Taiwan Ltd; Johnson & Johnson Taiwan Ltd
Completed - verified April 2012 - Condition: Schizophrenia
Intervention: Drug: Paliperidone ER
Sponsors: Johnson & Johnson Taiwan Ltd; Johnson & Johnson Taiwan Ltd
Completed - verified April 2012 - Conditions: Depressive Disorder, Major; Depressive Disorder, Minor; Dysthymic Disorder
Interventions: Other: RESPECT-D; Other: RESPECT-D-E (Enhanced)
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center; Johnson & Johnson
Recruiting - verified April 2012 - Condition: Pulmonary Tuberculosis
Interventions: Biological: ID93 + GLA-SE; Biological: ID93 alone
Sponsors: Infectious Disease Research Institute; Infectious Disease Research Institute; Aeras Global TB Vaccine Foundation; Bill and Melinda Gates Foundation; Paul G. Allen Family Foundation
Not yet recruiting - verified May 2012 - Condition: HIV Dementia
Interventions: Drug: Long acting methylphenidate; Drug: Long acting methylphenidate; Drug: Matched placebo
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified May 2012 - Condition: Influenza (Pandemic)
Interventions: Biological: Monovalent Avian Influenza VLP (H5N1); Biological: Monovalent Avian Influenza VLP (H5N1); Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant; Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant; Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant; Biological: Saline Placebo
Sponsors: Novavax; Novavax; Department of Health and Human Services
Recruiting - verified May 2012 - Condition: Influenza (Pandemic)
Interventions: Biological: Monovalent Avian Influenza VLP (H5N1); Biological: Monovalent Avian Influenza VLP (H5N1); Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant; Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant; Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant; Biological: Saline placebo
Sponsors: Novavax; Novavax; Department of Health and Human Services
Recruiting - verified May 2012 - Conditions: Magnesium Deficiency; Calcium Metabolism Disorders
Intervention: Dietary Supplement: vitamin D3
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; National Institutes of Health (NIH); National Institute on Aging (NIA)
Recruiting - verified May 2012 - Condition: Total Hip Arthroplasty
Interventions: Device: Total hip replacement with titanium shell and CORAIL stem; Device: Total hip replacement with metal-on-poly implant (PROFEMUR)
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Johnson & Johnson
Not yet recruiting - verified March 2012 - Condition: Bacterial Contamination
Interventions: Other: Antimicrobial impregnated scrubs; Other: Non-impregnated scrubs
Sponsors: University of Maryland; University of Maryland
Enrolling by invitation - verified May 2012 - Condition: Lung Cancer
Intervention:
Sponsors: Baptist Cancer Institute; Douglas W. Johnson MD, FACR
Recruiting - verified April 2012 - Condition: Hemoperitoneum
Intervention: Procedure: expired air
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio
Completed - verified May 2012 - Condition: Pain
Interventions: Drug: Ibuprofen; Drug: Ibuprofen
Sponsors: Johnson & Johnson Consumer and Personal Products Worldwide; McNeil AB; Johnson & Johnson Consumer and Personal Products Worldwide
Completed - verified May 2012 - Condition: Alcoholism
Interventions: Drug: Ondansetron + Brief Behavioral Enhancement Treatment; Drug: Placebo + Brief Behavioral Enhancement Treatment
Sponsors: University of Virginia; Bankole Johnson; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Not yet recruiting - verified May 2012 - Conditions: Chemical Injuries; Unspecified Complication of Corneal Transplant; Autoimmune Diseases; Ocular Cicatricial Pemphigoid; Stevens Johnson Syndrome; Lupus Erythematosus, Systemic; Rheumatoid Arthritis; Other Autoimmune Diseases
Intervention: Drug: Riboflavin
Sponsors: Massachusetts Eye and Ear Infirmary; Massachusetts Eye and Ear Infirmary
Recruiting - verified April 2012 - Condition: Substance Abuse Detection
Interventions: Drug: Tapentadol IR; Drug: Oxycodone IR
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed - verified March 2012 - Condition: Shock
Interventions: Drug: Ascorbic Acid; Other: Ringers Lactate or Normal Saline
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey
Not yet recruiting - verified February 2012 - Condition: Operable Early Stage NSCLC by the VATS Approach
Intervention:
Sponsors: University of Alberta; University of Alberta; Johnson & Johnson
Recruiting - verified March 2012 - Condition: Cow's Milk Allergy
Intervention: Other: Amino Acid formula
Sponsors: Mead Johnson Nutrition; Mead Johnson Nutrition
Recruiting - verified April 2012 - Conditions: Pain; Otitis Media
Interventions: Drug: benzocaine; Drug: placebo
Sponsors: Arbor Pharmaceuticals, Inc.; Arbor Pharmaceuticals, Inc.
Not yet recruiting - verified April 2012 - Conditions: Sickle Cell Disease; Sickle Cell Anemia; Sickle Cell Disorders; Hemoglobin S Disease; Sickling Disorder Due to Hemoglobin S
Interventions: Drug: HQK-1001; Drug: Placebo
Sponsors: HemaQuest Pharmaceuticals Inc.; HemaQuest Pharmaceuticals Inc.
Not yet recruiting - verified May 2012 - Conditions: Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia
Intervention: Drug: hLL1-DOX (IMMU-115)
Sponsors: Immunomedics, Inc.; Immunomedics, Inc.
Not yet recruiting - verified April 2012 - Conditions: Probable Migraine; Migraine With Aura; Migraine Without Aura
Interventions: Drug: Ketorolac Tromethamine; Drug: Metoclopramide
Sponsors: University of Alberta; University of Alberta; Canadian Institutes of Health Research (CIHR)
Not yet recruiting - verified May 2012 - Condition: Cystic Fibrosis
Intervention:
Sponsors: Foundation for the National Institutes of Health; Foundation for the National Institutes of Health; University of Southern California; University of Minnesota - Clinical and Translational Science Institute; M.D. Anderson Cancer Center; Dana-Farber Cancer Institute; Brigham and Women's Hospital; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Amgen; AstraZeneca; Eli Lilly and Company; Johnson & Johnson; Merck; Pfizer; Critical Path Institute; Predictive Safety Testing Consortium
Recruiting - verified March 2012 - Conditions: Sleep Apnea; Obesity
Intervention:
Sponsors: MetroHealth Medical Center; MetroHealth Medical Center; Robert Wood Johnson Foundation
Completed - verified April 2012 - Conditions: Conduct Disorder; Depression; Anxiety
Intervention: Behavioral: Animal-assisted intervention
Sponsors: Wayne State University; Wayne State University; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012 - Condition: Healthy Volunteers
Interventions: Drug: Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay; Drug: Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed - verified February 2012 - Conditions: Lung Cancer; Solid Tumor (Not Breast or Prostate Cancers)
Intervention: Drug: Cabozantinib
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Not yet recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate; Drug: prednisone; Drug: veliparib
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: WorkStation Intervention; Usual Working Condition
Interventions: Behavioral: WorkStation; Behavioral: Usual Working Condition
Sponsors: Pennington Biomedical Research Center; Pennington Biomedical Research Center; Blue Cross Blue Shield
Recruiting - verified April 2012 - Condition: Obesity
Interventions: Behavioral: Adapted Dietary Guidelines; Behavioral: Adapted Physical Activity Guidelines
Sponsors: Pennington Biomedical Research Center; Pennington Biomedical Research Center
Recruiting - verified April 2012 - Condition: Tinea Pedis
Interventions: Drug: Butenafine HCl Cream, 1%; Drug: Lotrimin Ultra®; Drug: Butenafine Vehicle
Sponsors: Taro Pharmaceuticals USA; Taro Pharmaceuticals USA
Recruiting - verified April 2012 - Condition: Schizophrenia
Intervention: Drug: Paliperidone palmitrate
Sponsors: Johnson & Johnson Pte Ltd; Johnson & Johnson Pte Ltd
Not yet recruiting - verified April 2012 - Conditions: Feeding Disorder; Nutrition Disorder; Infant,Premature
Interventions: Drug: Metclopramide; Drug: Erythromycin; Drug: placebo
Sponsors: East Tennessee State University; East Tennessee State University
Recruiting - verified March 2012 - Conditions: Cancer; Neoplasms; Lymphoma; Non-Hodgkin; B-Cell
Intervention: Drug: Chi Lob 7/4 (A chimeric monoclonal antibody)
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified April 2012 - Condition: X-linked Hypohidrotic Ectodermal Dysplasia
Intervention: Drug: EDI200
Sponsors: Edimer Pharmaceuticals; Edimer Pharmaceuticals
Not yet recruiting - verified March 2012 - Condition: Healthcare-acquired Infection
Intervention: Other: Copper-alloy surfaced patient care objects
Sponsors: Medical University of South Carolina; Medical University of South Carolina; Memorial Sloan-Kettering Cancer Center; Ralph H. Johnson VA Medical Center
Completed - verified December 2011 - Conditions: Major Depression; Dysthymic Disorder; Both Major Depression and Dysthymic Disorder
Intervention: Other: IMPACT
Sponsors: University of California, Los Angeles; University of California, Los Angeles; John A. Hartford Foundation; California HealthCare Foundation; Hogg Foundation; Robert Wood Johnson Foundation
Completed - verified March 2012 - Condition: Schizophrenia
Intervention: Drug: Lurasidone
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012 - Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Drug: Placebo
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Not yet recruiting - verified May 2012 - Condition: Shoulder Dislocation
Intervention: Device: MG-1
Sponsors: Johnson & Johnson K.K. Medical Company; Johnson & Johnson K.K. Medical Company
Enrolling by invitation - verified March 2012 - Condition: Healthy
Interventions: Drug: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets); Drug: B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed - verified February 2012 - Condition: Influenza
Intervention: Biological: VAX161 [STF2.HA5 H5N1]
Sponsors: VaxInnate Corporation; VaxInnate Corporation
Not yet recruiting - verified March 2012 - Condition: Atrial Fibrillation
Intervention: Drug: Dabigatran etexilate (Pradaxa)
Sponsors: University of Utah; University of Utah
Recruiting - verified March 2012 - Condition: Asthma
Interventions: Drug: Placebo; Drug: JNJ-39758979 30 mg/d; Drug: JNJ-39758979 100 mg/d; Drug: JNJ-39758979 300 mg/d
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Withdrawn - verified May 2012 - Condition: HIV-1 Infection
Intervention: Drug: Sevelamer carbonate
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: Coronary Artery Disease
Intervention:
Sponsors: Baylor Research Institute; Baylor Research Institute; Maquet Cardiovascular
Recruiting - verified March 2012 - Condition: Contrast Induced Acute Kidney Injury
Intervention: Drug: Contrast Enhanced Ultrasound (CEUS)
Sponsors: University of Virginia; University of Virginia; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2012 - Condition: Coronary Artery Disease
Interventions: Procedure: Implantation of coronary stent in bifurcation lesion; Procedure: Implantation of coronary stent in bifurcation lesion
Sponsors: Skejby Hospital; Leif Thuesen, MD, Head of the cath. lab.; Johnson & Johnson
Recruiting - verified February 2012 - Condition: COCAINE-RELATED DISORDERS
Interventions: Drug: d-cycloserine; Drug: sugar pill
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012 - Condition: Healthy Volunteers
Interventions: Drug: Treatment A: Hydromorphone 8 mg; Drug: Treatment B: Hydromorphone 16 mg; Drug: Treatment C: Hydromorphone 32 mg; Drug: Treatment D: Hydromorphone 64 mg
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed - verified December 2011 - Condition: Cornea Tissue Preservation Time
Intervention: Biological: Cornea tissue transplant
Sponsors: Case Western Reserve University; Case Western Reserve University; National Eye Institute (NEI); Jaeb Center for Health Research
Recruiting - verified May 2012 - Condition: Herpes Labialis
Intervention: Device: Patch ( Compeed© Total CareTM Cold Sore Patch)
Sponsors: Johnson & Johnson Consumer and Personal Products Worldwide; Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.
Completed - verified April 2012 - Condition: Venous Thrombosis
Interventions: Drug: Warfarin (Coumadin); Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Placebo; Drug: Vitamin K (Konakion)
Sponsors: Bayer; Bayer; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed - verified March 2012 - Condition: 21-hydroxylase Deficiency
Intervention: Drug: Abiraterone acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012 - Condition: Acute GvHD
Interventions: Biological: ALD518; Biological: ALD518; Biological: ALD518
Sponsors: Alder Biopharmaceuticals, Inc.; Alder Biopharmaceuticals, Inc.
Recruiting - verified March 2012 - Conditions: Ocular Hypertension; Open Angle Glaucoma
Interventions: Drug: AR-13324 Ophthalmic Solution 0.01%; Drug: AR-13324 Ophthalmic Solution 0.02%; Drug: AR-13324 Ophthalmic Solution 0.04%; Drug: AR-13324 Vehicle Ophthalmic Solution
Sponsors: Aerie Pharmaceuticals; Aerie Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Bronchopulmonary Dysplasia (BPD); Pulmonary Hypertension (PH)
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified April 2012 - Condition: Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
Interventions: Drug: dalcetrapib; Drug: Placebo; Other: Background care
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Tobacco Dependence
Interventions: Drug: Nicotine; Drug: Nicotine
Sponsors: Johnson & Johnson Consumer and Personal Products Worldwide; Johnson & Johnson Consumer and Personal Products Worldwide
Completed - verified January 2012 - Condition: Trisomy 21
Intervention:
Sponsors: Aria Diagnostics, Inc.; Aria Diagnostics, Inc.; Perinatal Quality Foundation: Nuchal Translucency Quality Review
Not yet recruiting - verified January 2012 - Conditions: Insomnia; Nocturnal Awakening; Irritability; Coping Behavior; Stress
Interventions: Dietary Supplement: 5-Aminolevulinic Acid (5-ALA); Dietary Supplement: Placebo
Sponsors: University of Hawaii; University of Hawaii; SBI ALApromo Co., Ltd. - Strategic Business Innovator
Recruiting - verified February 2012 - Condition: Skin Cancer
Interventions: Behavioral: Appearance-Focused Website Intervention; Behavioral: Control Website
Sponsors: East Tennessee State University; East Tennessee State University
Enrolling by invitation - verified January 2012 - Condition: Diarrhea
Interventions: Drug: Racecadotril; Drug: Racecadotril; Drug: Racecadotril; Drug: Racecadotril
Sponsors: Johnson & Johnson Consumer and Personal Products Worldwide; Johnson & Johnson Consumer and Personal Products Worldwide
Completed - verified January 2012 - Condition: Obesity
Intervention: Behavioral: Discount intervention
Sponsors: New York Obesity and Nutrition Research Center; New York Obesity and Nutrition Research Center; Robert Wood Johnson Foundation; Columbia University
Enrolling by invitation - verified January 2012 - Conditions: Ulcerative Colitis; Crohn's Disease; Inflammatory Bowel Disease
Interventions: Dietary Supplement: AndoSan; Dietary Supplement: Sugar Extract
Sponsors: Oslo University Hospital; Oslo University Hospital; ImmunoPharma
Recruiting - verified December 2011 - Condition: Cytomegalovirus Disease
Interventions: Drug: Valganciclovir; Biological: CMV hyperimmune globulin; Drug: Valganciclovir
Sponsors: Medical University of South Carolina; Medical University of South Carolina; CSL Behring
Recruiting - verified December 2011 - Condition: Shoulder Impingement Syndrome
Intervention: Other: Shoulder resistive exercise
Sponsors: Texas Woman's University; Texas Woman's University
Recruiting - verified March 2012 - Condition: Healthy
Interventions: Drug: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets); Drug: B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed - verified February 2012 - Condition: Papulopustular Rosacea (PPR)
Interventions: Drug: CD5024; Drug: Azelaic acid 15% Gel
Sponsors: Galderma; Galderma
Recruiting - verified April 2012 - Condition: Posttraumatic Stress Disorder
Interventions: Behavioral: MBSR Meditation; Behavioral: Present Centered Group Therapy (PCGT)
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified February 2012 - Condition: Non-anemic Iron Deficiency
Interventions: Dietary Supplement: Ferrous Sulfate; Dietary Supplement: Placebo; Other: No intervention; Behavioral: Dietary counseling
Sponsors: The Hospital for Sick Children; The Hospital for Sick Children; Canadian Institutes of Health Research (CIHR); Mead Johnson Nutrition; Mount Sinai Hospital, Canada; St. Michael's Hospital, Toronto
Not yet recruiting - verified November 2011 - Conditions: Acute Respiratory Infection; Diarrheal Disease
Interventions: Dietary Supplement: Cow's milk; Dietary Supplement: Follow-On Formula
Sponsors: Mead Johnson Nutrition; Mead Johnson Nutrition; Shanghai Children Medical Center; Shanghai, China
Active, not recruiting - verified December 2011 - Condition: Type 2 Diabetes
Intervention:
Sponsors: Foundation for the National Institutes of Health; Foundation for the National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Juvenile Diabetes Research Foundation; Amylin Pharmaceuticals, Inc.; Merck; Pfizer; Eli Lilly and Company; Takeda Global Research & Development Center, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Novartis
Recruiting - verified October 2011 - Condition: Chronic Rhinosinusitis
Interventions: Device: Relieva Balloon Sinuplasty™ System; Procedure: Functional Endoscopic Sinus Surgery
Sponsors: Johnson & Johnson Medical Companies; Johnson & Johnson Medical Companies; Acclarent
Recruiting - verified March 2012 - Condition: Squamous Cell Carcinoma Of The Head And Neck
Interventions: Drug: Cetuximab; Drug: Dasatinib
Sponsors: University of Pittsburgh; University of Pittsburgh; Bristol-Myers Squibb
Recruiting - verified December 2011 - Condition: Melanoma
Interventions: Biological: Plasmid INTERLEUKIN-12; Device: Intratumoral Electroporation
Sponsors: University of California, San Francisco; University of California, San Francisco; OncoSec Medical Incorporated
Recruiting - verified April 2012 - Condition: Spondylitis, Ankylosing
Interventions: Drug: Golimumab; Drug: Placebo
Sponsors: Schering-Plough; Schering-Plough; Johnson & Johnson
Recruiting - verified April 2012 - Condition: Cancer
Intervention:
Sponsors: Caris Science, Inc.; Caris Science, Inc.
Recruiting - verified February 2012 - Conditions: Hip Osteoarthritis; Knee Osteoarthritis
Intervention: Other: Shared Decision Making Intervention
Sponsors: University of California, San Francisco; University of California, San Francisco; Stanford University; Robert Wood Johnson Foundation
Recruiting - verified February 2012 - Condition: Spinal Muscular Atrophy
Intervention: Drug: ISIS-SMNRx
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Kidney Cancer; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206; Drug: hydroxychloroquine; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Cancer Institute of New Jersey; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Allergy to Mold
Interventions: Other: Air Structuring Protein; Other: Placebo sorbet
Sponsors: Unilever SEAC; Unilever SEAC
Recruiting - verified December 2011 - Condition: Adolescent Oncology Patients
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified November 2011 - Condition: Schizophrenia
Interventions: Drug: TC-5619 5mg; Drug: TC-5619 50mg; Drug: Placebo
Sponsors: Targacept Inc.; Targacept Inc.
Recruiting - verified May 2012 - Condition: Prostate Cancer
Intervention: Drug: 99mTc-MIP-1404
Sponsors: Molecular Insight Pharmaceuticals, Inc.; Molecular Insight Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Condition: Tobacco Dependence
Interventions: Drug: Nicotine; Drug: Nicotine; Drug: Nicotine
Sponsors: Johnson & Johnson Consumer and Personal Products Worldwide; Johnson & Johnson Consumer and Personal Products Worldwide
Completed - verified September 2011 - Condition: Dexmedetomidine Induced Sedation
Intervention: Drug: dexmedetomidine
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified April 2012 - Condition: Femur Neck Fracture
Interventions: Drug: Teriparatide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Dry Eye Syndromes
Intervention: Other: Eye Drops with Experimental Preservative
Sponsors: Johnson & Johnson Consumer and Personal Products Worldwide; Johnson & Johnson Consumer and Personal Products Worldwide
Completed - verified September 2011 - Conditions: Infiltration; Extravasation; IV Infiltration; IV Extravasation; Extravasation of Diagnostic and Therapeutic Materials
Intervention:
Sponsors: ivWatch, LLC; ivWatch, LLC
Completed - verified November 2011 - Condition: Painful Osteoporotic Vertebral Compression Fractures (VCF)
Interventions: Device: Vertebral Augmentation (STABILIT); Other: Non-operative Management
Sponsors: DFINE Inc.; DFINE Inc.
Recruiting - verified February 2012 - Condition: Therapeutic Equivalency
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors: Bayer; Bayer; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed - verified January 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: mibefradil dihydrochloride; Drug: temozolomide; Other: 3'-deoxy-3'-[18F]fluorothymidine; Other: pharmacological study
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI); Tau Therapeutics LLC
Recruiting - verified April 2012 - Condition: Diamond Blackfan Anemia
Intervention: Drug: Sotatercept
Sponsors: North Shore Long Island Jewish Health System; North Shore Long Island Jewish Health System
Recruiting - verified January 2012 - Condition: Schizophrenia
Intervention: Drug: Paliperidone palmitate
Sponsors: Janssen-Cilag Farmaceutica Ltda.; Janssen-Cilag Farmaceutica Ltda.
Recruiting - verified April 2012 - Condition: Healthy
Intervention: Drug: Canagliflozin/Probenecid
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed - verified February 2012 - Condition: Breast Cancer
Interventions: Device: MammaPrint; Device: BluePrint; Device: TargetPrint; Device: TheraPrint
Sponsors: Agendia; Agendia
Recruiting - verified April 2012 - Conditions: Cow's Milk Allergy; Intolerance to Extensively Hydrolyzed Formulas; Intolerance to Breast Milk
Interventions: Other: Amino Acid-based Formula with high DHA and ARA; Other: Amino Acid-based Formula with lower DHA and ARA
Sponsors: Mead Johnson Nutrition; Mead Johnson Nutrition
Withdrawn - verified March 2012 - Condition: Healthy
Intervention:
Sponsors: Boys Town National Research Hospital; Boys Town National Research Hospital; Mead Johnson Nutrition
Not yet recruiting - verified November 2011 - Conditions: Acute Renal Failure; Kidney Disease; Coronary Artery Disease
Interventions: Drug: IV isotonic saline; Drug: IV isotonic bicarbonate; Drug: N-acetylcysteine; Drug: Placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; The George Institute for Global Health
Not yet recruiting - verified March 2012 - Condition: Osteoarthritis, Knee
Intervention:
Sponsors: Orthosensor, Inc.; Orthosensor, Inc.
Recruiting - verified January 2012 - Condition: Rheumatoid Arthritis
Intervention: Drug: JNJ-39758979 / MTX
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed - verified March 2012 - Condition: Malignant Glioma
Intervention: Procedure: laser interstitial thermal therapy
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; Cancer Institute of New Jersey
Recruiting - verified January 2012 - Condition: Soft Tissue Sarcoma
Intervention: Drug: Trabectedin
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
No longer available - verified August 2011 - Condition: Squamous Cell Lung Cancer
Intervention: Drug: Dasatinib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified December 2011 - Condition: Interstitial Cystitis
Interventions: Drug: Lidocaine Releasing Intravesical System - LiRIS®; Other: LiRIS Placebo; Procedure: Sham
Sponsors: TARIS Biomedical, Inc.; TARIS Biomedical, Inc.
Recruiting - verified May 2012 - Condition: Smoking Cessation
Interventions: Drug: Placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Intercritical Gout
Interventions: Drug: Colchicine; Drug: Placebo; Drug: Allopurinol
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Intervention:
Sponsors: Multiple Myeloma Research Foundation; Multiple Myeloma Research Foundation; Translational Genomics Research Institute, Phoenix, Arizona.; Spectrum Health Hospitals; Van Andel Research Institute; Quintiles
Recruiting - verified May 2012 - Condition: Fibromyalgia
Interventions: Drug: Quetiapine; Drug: Placebo
Sponsors: East Tennessee State University; East Tennessee State University; AstraZeneca
Recruiting - verified October 2011 - Condition: Leukemia, Pediatric
Intervention: Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Children's Oncology Group; EsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib
Recruiting - verified April 2012 - Conditions: Diabetic Nephropathy; Type 2 Diabetes Mellitus
Interventions: Drug: Placebo; Drug: CCX140-B; Drug: CCX140-B
Sponsors: ChemoCentryx; ChemoCentryx
Recruiting - verified May 2012 - Conditions: Pulmonary Arterial Hypertension; Heart Failure
Interventions: Drug: Apelin; Drug: Saline (Placebo); Drug: Saline (Placebo); Drug: Apelin
Sponsors: Golden Jubilee National Hospital; Golden Jubilee National Hospital; NHS Lothian; Imperial College Healthcare NHS Trust
Not yet recruiting - verified October 2011 - Condition: Ischemia Reperfusion Injury
Intervention: Drug: Treprostinil
Sponsors: University of Pittsburgh; University of Pittsburgh
Not yet recruiting - verified January 2012 - Conditions: Multiple Myeloma; Solid Tumors
Intervention: Drug: LY2812176
Sponsors: Dekkun Corporation; Dekkun Corporation
Recruiting - verified October 2011 - Conditions: Diabetic Nephropathy; Type 2 Diabetes Mellitus
Interventions: Drug: Placebo; Drug: CCX140-B
Sponsors: ChemoCentryx; ChemoCentryx
Recruiting - verified September 2011 - Conditions: Myocardial Infarction; Ventricular Dysfunction; Sudden Death; Ventricular Tachycardia; Ventricular Fibrillation
Intervention: Device: wearable defibrillator
Sponsors: Zoll Medical Corporation; Zoll Medical Corporation; University of California, San Francisco
Recruiting - verified May 2012 - Condition: HIV-1 Infection
Intervention: Drug: Rifaximin
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Condition: Healthy
Interventions: Drug: Rifampin; Drug: Canagliflozin
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed - verified February 2012 - Condition: Schizophrenia
Intervention: Drug: paliperidone
Sponsors: Seoul National University Hospital; Seoul National University Hospital; Johnson & Johnson
Recruiting - verified May 2012 - Conditions: Mycobacterium Ulcerans Disease; Buruli Ulcer
Intervention: Procedure: surgical intervention on Buruli ulcer
Sponsors: University Medical Centre Groningen; University Medical Centre Groningen; PNLUB, Ministère de la santé, Cotonou, République du Bénin.; Laboratoire de Référence des Mycobactéries (LRM) Cotonou
Recruiting - verified September 2011 - Conditions: Acute Respiratory Infection; Diarrheal Disease
Interventions: Dietary Supplement: Cow's milk; Dietary Supplement: Follow-On Formula
Sponsors: Mead Johnson Nutrition; Mead Johnson Nutrition; Federal University of Bahia, Salvador, Bahia, Brazil
Active, not recruiting - verified October 2011 - Conditions: Chronic Kidney Disease; Secondary Hyperparathyroidism
Intervention: Drug: Contrast Enhanced Ultrasonography
Sponsors: University of Virginia; University of Virginia
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Biological: Ramucirumab (IMC-1121B); Drug: Eribulin
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified May 2012 - Condition: Schizophrenia
Interventions: Drug: Lurasidone; Drug: Matching Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012 - Condition: Acute Gouty Arthritis
Intervention: Drug: Canakinumab 150mg in prefilled syringe
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Obstructive Sleep Apnea
Intervention: Device: Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical )
Sponsors: Apnex Medical, Inc.; Apnex Medical, Inc.
Recruiting - verified December 2011 - Condition: Healthy
Interventions: Device: All-in-One Light multipurpose; Device: Aquify care
Sponsors: Sauflon Pharmaceuticals Ltd; Sauflon Pharmaceuticals Ltd
Completed - verified July 2011 - Conditions: Homeless Persons; Primary Health Care
Intervention: Behavioral: Embedded Peer Mentor
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified March 2012 - Condition: Opioid Dependence
Intervention:
Sponsors: Alkermes; Alkermes
Recruiting - verified April 2012 - Condition: Chronic Idiopathic Constipation
Intervention: Drug: plecanatide
Sponsors: Synergy Pharmaceuticals, Inc.; Synergy Pharmaceuticals, Inc.; PAREXEL International
Recruiting - verified April 2012 - Condition: Atopic Dermatitis
Interventions: Other: Cetaphil Restoraderm; Other: Standard of Care
Sponsors: Oregon Health and Science University; Oregon Health and Science University; Galderma
Recruiting - verified June 2011 - Conditions: ICU Delirium; Immobility
Intervention:
Sponsors: University of Nebraska; University of Nebraska; Robert Wood Johnson Foundation
Recruiting - verified April 2012 - Conditions: Sedentary Lifestyle; Stress, Psychological; Healthy Eating
Intervention: Behavioral: liveWell: A healthy foundation for life
Sponsors: Pro-Change Behavior Systems; Pro-Change Behavior Systems
Active, not recruiting - verified March 2012 - Condition: Hand Hygiene Behavior
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Enrolling by invitation - verified August 2011 - Conditions: Posttraumatic Stress Disorder; Traumatic Brain Injury
Interventions: Drug: Methylphenidate Hydrochloride 20 mg; Drug: Placebo Capsule; Drug: Galantamine 12 mg
Sponsors: INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium; INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium; U.S. Army Medical Research and Materiel Command
Recruiting - verified January 2012 - Condition: Rheumatoid Arthritis
Intervention: Drug: JNJ-38518168 / MTX
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed - verified February 2012 - Condition: Breast Cancer
Interventions: Device: AeroForm Patient Controlled Tissue Expander; Procedure: Implantation of Saline Tissue Expander
Sponsors: AirXpanders, Inc.; AirXpanders, Inc.
Recruiting - verified April 2012 - Condition: Stroke
Intervention: Other: Commercially-Available Interactive Video Games
Sponsors: University of South Carolina; University of South Carolina
Completed - verified August 2011 - Condition: Major Depressive Disorder
Interventions: Drug: Lurasidone 20 mg; Drug: Lurasidone 60 mg; Drug: Placebo
Sponsors: Sunovion; Sunovion
Not yet recruiting - verified November 2011 - Condition: Major Depressive Disorder
Intervention: Drug: Lurasidone
Sponsors: Sunovion; Sunovion
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Canagliflozin 300mg/Placebo; Drug: Canagliflozin 300mg/Canagliflozin 150mg; Drug: Canagliflozin 300mg
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Completed - verified December 2011 - Conditions: Cystic Fibrosis; Growth Failure
Intervention:
Sponsors: Ramsey, Bonnie, MD; Ramsey, Bonnie, MD; Cystic Fibrosis Foundation
Recruiting - verified May 2012 - Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012 - Conditions: Crohn's Disease; Inflammatory Bowel Disease; IBD; Colitis
Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo; Drug: Group 2 ustekinumab 130 mg
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012 - Conditions: Crohn's Disease; Colitis; IBD; Inflammatory Bowel Disease
Interventions: Drug: Placebo; Drug: Ustekinumab; Drug: Ustekinumab; Drug: Ustekinumab; Drug: Ustekinumab
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Enrolling by invitation - verified May 2012 - Condition: Neurofibromatosis Type 1
Intervention:
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified September 2011 - Condition: Tobacco Dependence
Interventions: Drug: Nicotine; Drug: Nicotine
Sponsors: Johnson & Johnson Consumer and Personal Products Worldwide; Johnson & Johnson Consumer and Personal Products Worldwide
Completed - verified October 2011 - Conditions: Cognitive/Functional Effects; Leukemia; Neurotoxicity; Pain; Therapy-related Toxicity
Interventions: Drug: clofarabine; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: hydrocortisone sodium succinate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Prostate Cancer
Intervention: Drug: Leuprolide acetate 22.5 mg depot, GP-Pharm SA
Sponsors: GP-Pharm; GP-Pharm
Recruiting - verified March 2012 - Condition: Uncontrolled Hypertension
Intervention: Device: Renal denervation (Symplicity Catheter System)
Sponsors: Medtronic Vascular; Medtronic Vascular
Recruiting - verified May 2012 - Conditions: Cervical Cancer; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Sexuality and Reproductive Issues
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Bladder Cancer
Interventions: Drug: Apaziquone; Drug: Placebo
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc; Allergan
Recruiting - verified April 2012 - Conditions: Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: paclitaxel; Drug: carboplatin; Drug: vorinostat; Other: placebo; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: protein analysis; Genetic: gene expression analysis; Genetic: proteomic profiling
Sponsors: California Cancer Consortium; California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Traumatic Brain Injury; Posttraumatic Stress Disorder
Interventions: Behavioral: Cognitive Rehabilitation Intervention; Behavioral: Cognitive Rehabilitation Control Intervention
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill
Not yet recruiting - verified December 2011 - Condition: Rheumatoid Arthritis
Interventions: Drug: MRC375; Drug: Matching Placebo; Drug: MRC375 150mg
Sponsors: Molecular Research Center, Inc.; Molecular Research Center, Inc.; Camargo Pharmaceutical Services; Rho; Clin Data Services; Harrison Clinical Research; BARC Global Central Laboratory; Bilcare Global Clinical Supplies
Recruiting - verified January 2012 - Conditions: Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Lymphoma; Neurotoxicity; Radiation Toxicity
Interventions: Biological: rituximab; Drug: cytarabine; Drug: methotrexate; Drug: procarbazine hydrochloride; Drug: vincristine sulfate; Radiation: whole-brain radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: HIV-1 Infection
Interventions: Drug: Atripla; Drug: Calcium Carbonate; Drug: Vitamin D3; Drug: Placebo for calcium carbonate; Drug: Placebo for vitamin D3
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: Hypoglycemia
Intervention: Drug: Eplerenone
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; Robert Wood Johnson Foundation
Recruiting - verified July 2011 - Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified August 2011 - Conditions: Nicotine Dependence; Opiate Dependence
Interventions: Behavioral: Intensive, tailored intervention; Behavioral: NJ Quitline Referral
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Institute on Drug Abuse (NIDA)
Recruiting - verified January 2012 - Conditions: Metastatic ER+ Her2- Breast Cancer; Postmenopausal
Interventions: Drug: Exemestane; Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane; Drug: Abiraterone acetate + Prednisone or Prednisolone
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012 - Condition: Pulmonary Arterial Hypertension
Intervention:
Sponsors: Actelion; Actelion; Canadian Heart Research Centre
Recruiting - verified April 2012 - Condition: Schizophrenia
Intervention: Drug: OPC-34712
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified March 2012 - Condition: Acute Schizophrenia
Interventions: Drug: OPC-34712; Drug: OPC-34712; Drug: OPC-34712; Drug: Placebo
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Secukinumab (75 mg); Drug: Secukinumab (150 mg); Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Bronchoconstriction; Asthma
Intervention: Device: AlphaCore System
Sponsors: ElectroCore LLC; ElectroCore LLC
Suspended - verified December 2011 - Condition: Leukemia
Interventions: Drug: asparaginase; Drug: bortezomib; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: mitoxantrone hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Respiratory Symptoms; Signs and Symptoms, Digestive; Anemia
Intervention:
Sponsors: Mead Johnson Nutrition; Mead Johnson Nutrition
Active, not recruiting - verified September 2011 - Condition: Hereditary Angioedema
Intervention: Drug: icatibant
Sponsors: Shire Human Genetic Therapies, Inc.; Shire Human Genetic Therapies, Inc.
Recruiting - verified May 2012 - Conditions: Segmental and Somatic Dysfunction; Pathological Conditions, Signs and Symptoms; Ectopic Intestinal Mucosa
Intervention:
Sponsors: A.T. Still University of Health Sciences; A.T. Still University of Health Sciences
Recruiting - verified June 2011 - Condition: Cancer
Interventions: Drug: prasterone; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Congenital Cytomegalovirus Infection; Maternal Cytomegalovirus Infection
Intervention: Drug: CMV hyperimmune globulin
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not yet recruiting - verified June 2011 - Condition: Leukemia
Interventions: Drug: tipifarnib; Genetic: protein expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified May 2011 - Conditions: Peripheral Arterial Disease; Claudication
Intervention:
Sponsors: University of Washington; University of Washington
Recruiting - verified February 2012 - Condition: Organ Transplantation
Intervention:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: paclitaxel; Other: pharmacological study; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified May 2012
 |
Johnson & Johnson - Database of Clinical Trials by Pharmaceutical Companies |
